Cargando…

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab

IMPORTANCE: Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) shows frequent and durable responses to programmed cell death 1 blockade. While most of these tumors are sporadic and observed in older patients, first-line pembrolizumab data are limited to findings from the K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saberzadeh-Ardestani, Bahar, Jones, Jeremy C., Hubbard, Joleen M., McWilliams, Robert R., Halfdanarson, Thorvardur R., Shi, Qian, Sonbol, Mohamad Bassam, Ticku, Jonathan, Jin, Zhaohui, Sinicrope, Frank A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947726/ https://www.ncbi.nlm.nih.gov/pubmed/36811859 http://dx.doi.org/10.1001/jamanetworkopen.2023.0400

Ejemplares similares

Synchronous Neoplasia Rates at Colonoscopic Diagnosis of Early-Onset vs Average-Onset Colorectal Cancer
por: Emiloju, Oluwadunni E., et al.
Publicado: (2023)

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
por: Jin, Zhaohui, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Mayo Clinic Cancer Center Experience of Metastatic Extramammary Paget Disease 1998-2012
por: Padrnos, Leslie, et al.
Publicado: (2016)

Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016
por: Elmehrath, Ahmed O., et al.
Publicado: (2021)

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
por: Mettu, Niharika B., et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
por: Le, Dung T., et al.
Publicado: (2020)

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma
por: Dollin, Yonatan, et al.
Publicado: (2020)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab
por: Singh, Arminder, et al.
Publicado: (2021)

Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers
por: Yoon, Harry H., et al.
Publicado: (2018)

Metastatic basal cell carcinoma with loss of p63 and mismatch repair proteins
por: Johnson, Nathan M., et al.
Publicado: (2017)

Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer
por: Huang, Qianpeng, et al.
Publicado: (2023)

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
por: Gallois, Claire, et al.
Publicado: (2023)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer
por: Meng, Lingbin, et al.
Publicado: (2023)

Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants
por: Ojini, Irene, et al.
Publicado: (2015)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
por: Barnhart, Carrie
Publicado: (2015)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
por: Song, Yurong, et al.
Publicado: (2023)

MutSα mismatch repair protein stability is governed by subunit interaction, acetylation, and ubiquitination
por: Arlow, Tim, et al.
Publicado: (2021)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

Mutation Rates, Spectra, and Genome-Wide Distribution of Spontaneous Mutations in Mismatch Repair Deficient Yeast
por: Lang, Gregory I., et al.
Publicado: (2013)

Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry
por: Jung, Jiyoon, et al.
Publicado: (2017)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
por: Song, Haa-Na, et al.
Publicado: (2018)

Pembrolizumab as first-line treatment for metastatic uveal melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma
por: Ferguson, Ian, et al.
Publicado: (2019)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

The Rate and Spectrum of Spontaneous Mutations in Mycobacterium smegmatis, a Bacterium Naturally Devoid of the Postreplicative Mismatch Repair Pathway
por: Kucukyildirim, Sibel, et al.
Publicado: (2016)

Safety and Outcomes of Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors
por: Gudmundsdottir, Hallbera, et al.
Publicado: (2022)

Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis
por: Pei, Rui, et al.
Publicado: (2021)

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
por: Eriksson, Jennifer, et al.
Publicado: (2019)

Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab
por: Casey, R.T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_49qssvvphp1ram1q2c22bbnejl